Drug Profile
Research programme: cancer therapeutics - Shanghai Hengrui Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Antineoplastics; Pyrroles; Vinca alkaloids
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; KIF11 protein inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China
- 10 Apr 2008 Preclinical trials in Cancer in China (unspecified route)